Date: 26 November 2013
Copyright: n/a
Notes:
MS is a 59 year old diabetic patient requiring insulin. He had asthma since childhood, previous episodes of vasculitis, a retinopathy and renal dysfunction. In 1997 Mycobacterium avium intracellulare infection of the lung was diagnosed and successfully treated over a 12 month period. Shortly after this treatment was completed an aspergilloma was noted in the right upper lobe in September 1998. This was untreated for 2 years with progressive enlargement of the cavity most consistent with chronic necrotising pulmonary aspergillosis (CNPA), until the patient became unwell, when benefit from itraconazole was seen. Unfortunately the patient subsequently developed a squamous cell carcinoma and died.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
